Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00610935 · ClinicalTrials.gov registry record · Phase 3
Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
A Phase 3 study, sponsored by BioCryst Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 82
- Enrollment target
NCT00610935 is a Phase 3 study that was terminated before completion, run by BioCryst Pharmaceuticals. The registered enrollment target is 82 participants.
The verdict
NCT00610935, a Phase 3 study, was terminated before completion, sponsored by BioCryst Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 82 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectivess of a single intramuscular injection of peramivir for the treatment of subjects with acute, uncomplicated influenza.
Interventions
- DRUG Placebo
- DRUG Peramivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00610935
The ClinicalTrials.gov registry entry for NCT00610935 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00610935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00610935 about?
NCT00610935 is a clinical study titled "Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza". The purpose of this study is to determine the safety and effectivess of a single intramuscular injection of peramivir for the treatment of subjects with acute, uncomplicated influenza.
What is the current status of trial NCT00610935?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 82 participants. The study started on 2008-01. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00610935?
The interventions under investigation include: Placebo (DRUG), Peramivir (DRUG).
Who is sponsoring clinical trial NCT00610935?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.